BioCentury
ARTICLE | Distillery Therapeutics

Cancer

July 31, 2017 7:26 PM UTC

Cell culture and mouse studies suggest combining PARP and BET bromodomain proteins inhibitors could help treat homologous recombination (HR)-proficient cancers, including breast, ovarian and prostate cancers. In HR-proficient breast, ovarian and prostate cancer lines, the PARP inhibitor Lynparza olaparib plus a BET inhibitor tool compound increased DNA damage compared with either agent alone. In a xenograft mouse models of HR-proficient breast or ovarian cancer, the combination decreased tumor growth, and in the ovarian cancer model, it also decreased the volume of peritoneal ascites. Next steps could include testing combinations of other PARP and BET inhibitors in solid tumor models.

AstraZeneca plc markets Lynparza to treat BRCA-mutant ovarian cancer and has the compound in Phase III testing to treat pancreatic cancer and BRCA-deficient breast cancer, Phase II testing to treat solid tumors and BRCA-mutant prostate cancer, and Phase I testing to treat brain cancer...